CTCintia Kazuko Tokuhara

Cintia Kazuko Tokuhara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cintia Kazuko Tokuhara has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PHOSPHO1 deficiency delays osteogenic differentiation of osteoblasts, impairing mineralization and altering the protein composition of matrix vesicles

    by Luiz Henrique da Silva Andrilli, Cintia Kazuko Tokuhara, Larwsk Hayann Silva, Angie Puelles, Colin Farquharson, Ana Paula Ramos, Jose Luis Millán, Flavia Amadeu de Oliveira, Pietro Ciancaglini

    Matrix vesicles (MVs), a specialized class of extracellular vesicles, play a central role in skeletal mineralization. Phosphoethanolamine/phosphocholine phosphatase 1 (PHOSPHO1) generates inorganic phosphate (Pi) within the MV lumen and is considered essential for the initiation of mineralization. This study investigated the role of PHOSPHO1 in osteoblast differentiation and MV biology using primary calvariae osteoblasts from 6-day-old wild-type (WT) and Phospho1-/- mice. Cells were cultured under osteogenic conditions for 14 and 21 days, followed by analyses of cell viability, mineralization, gene expression, MV biophysical properties, and proteomic analyses. Phospho1-/- osteoblasts exhibited threefold higher mitochondrial activity than WT cells. Mineral deposition was detected only in WT cultures at day 21, indicating impaired mineralization in the absence of PHOSPHO1. Gene expression analysis revealed increased Alpl and Smpd3, and decreased Enpp1 expression in Phospho1-/- osteoblasts. Consistent with these findings, alkaline phosphatase (ALP) activity in MVs increased 7.5-fold between days 14 and 21 in both genotypes. Atomic force microscopy of MVs derived from Phospho1-/- osteoblasts exhibited a 6.5- and 2.1-fold reduction in vesicle volume and surface roughness, respectively, compared with WT MVs. Proteomic analysis revealed reduced tissue non-specific alkaline phosphatase (TNAP) at day 14, followed by increased TNAP levels at day 21, accompanied by decreased collagen XII and collagen VI content in Phospho1-/- MV preparations. Collectively, these findings indicate that cellular adaptation is insufficient to restore mineralization in the absence of PHOSPHO1. Instead, PHOSPHO1 appears to play a critical role in establishing the molecular and biophysical properties of MVs necessary for mineral nucleation and propagation.

  • Open Access

    Effects of comorbid chronic kidney disease on late-onset hypophosphatasia mice under treatment with asfotase alfa

    by Cintia Tokuhara, Flavia Amadeu de Oliveira, Sonoko Narisawa, Elis J Lira dos Santos, Brian L Foster, Jose Luis Millan

    Hypophosphatasia (HPP) is a rare bone disorder caused by loss-of-function mutations in the ALPL gene, leading to deficient tissue-nonspecific alkaline phosphatase (TNAP) activity and impaired skeletal/dental mineralization. Asfotase alfa (AA), the only FDA-approved therapy, improves survival and skeletal/dental mineralization. Because of its mineral-binding properties, AA also binds to sites of ectopic calcification, including vasculature. Overexpression of TNAP in either the vascular media or intima has been shown to induce severe calcification. Here, we examined what might occur if a disease that features medial artery calcification, such as CKD-mineral and bone disorder (CKD-MBD), were to develop in a subject with HPP undergoing AA treatment. Two-month-old AlplPrx1/− (HPP) or Alplflox/− (non-HPP control) mice were treated with s.c. AA injections (8.2 mg/kg, 3×/week) for 4 mo. After 3 mo of treatment, CKD was induced via a 0.2% adenine and 1.8% phosphorus diet. Mice were euthanized at 6 mo of age, and skeletal, renal, cardiac, and vascular tissues were analyzed. Alkaline phosphatase levels slightly increased with AA but significantly increased after inducing CKD in control and HPP female mice. In males, ALP activity was elevated in the AA and AA+CKD cohorts. Micro-CT analysis showed improved bone parameters in HPP under AA treatment. However, the improvements were dampened when CKD was induced, compared to non-CKD Alplflox/−. Immunohistochemistry of the kidney revealed increased TNAP immunolocalization in the AA+CKD cohort, in both females and males. Ectopic renal and vascular calcification was observed in the AA+CKD group. Gene expression profiling in the kidney revealed that AA treatment modulates the immune and mineral metabolism pathways, while CKD superimposition induces a shift toward pro-inflammatory and pro-fibrotic responses, compromising renal and skeletal homeostasis. These findings underscore the importance of carefully evaluating HPP patients under treatment with mineral-targeted TNAP at risk of developing comorbid conditions associated with ectopic calcification.

  • Open Access

    ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia

    by Sonoko Narisawa, Flavia Amadeu de Oliveira, Cintia Kazuko Tokuhara, Elis J Lira dos Santos, Elena Fonfria, Jennifer Batson, Zhiliang Cheng, Ann Houston, Brian L Foster, José Luis Millán

    Hypophosphatasia (HPP) is caused by loss-of-function mutations in the human ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP), whose deficiency results in the accumulation of the calcification inhibitor inorganic pyrophosphate (PPi), resulting in skeletal and dental hypomineralization. Enzyme replacement with mineral-targeted TNAP (asfotase alfa) improves skeletal mineralization but the almost daily injections of this biologic can lead to injection site reactions and discontinuation of treatment. Since PPi is produced by the enzymatic action of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) from adenosine triphosphate (ATP), we tested if ENPP1 could be a druggable target for the development of an alternative treatment for HPP, particularly for the non-lethal later-onset forms of HPP, where enzyme replacement is not currently approved. We orally administered 30 and 100 mg/kg/day of an ENPP1 inhibitor, REV102, to the AlplPrx1/− mouse model of late-onset HPP, for 105 days and confirmed target engagement, as plasma PPi concentrations were markedly reduced. X-ray, micro-CT, and bone morphometry indicated improvement in appendicular skeletal mineralization. This study suggests that the adult HPP phenotype could benefit from oral administration of ENPP1 inhibitors.


  • Preclinical evaluation of the efficacy and safety of adeno-associated virus 8-tissue-nonspecific alkaline phosphatase-D10 in Alpl-/- and AlplPrx1/Prx1 mouse models for the treatment of early and late-onset hypophosphatasia

    by Flavia Amadeu de Oliveira, Cintia Kazuko Tokuhara, Fatma F Mohamed, Sonoko Narisawa, Elis J Lira dos Santos, Natalie L Andras, Mohammad Shadid, Koichi Miyake, Brian L Foster, José Luis Millán

    We previously documented successful resolution of skeletal and dental disease in the infantile and late-onset murine models of hypophosphatasia (HPP) with a single injection of an adeno-associated serotype 8 vector encoding mineral-targeted TNAP (AAV8-TNAP-D10). Here, we conducted dosing studies in both HPP mouse models. A single escalating dose from 4 × 108 up to 4 × 1010 (vg/b) was intramuscularly injected into 4-day-old Alpl-/- mice (an infantile HPP model) and a single dose from 4 × 106 up to 4 × 109 (vg/b) was administered to 8-wk-old AlplPrx1/Prx1 mice (a late-onset HPP model). Wild-type littermates were used as controls. Serum alkaline phosphatase activity was increased, and PPi levels were decreased in a dose-dependent manner in both the Alpl-/- and AlplPrx1/Prx1 models. Radiographic and μCT analysis of long bones of female and male Alpl-/- mice showed full correction of skeletal phenotype at 4 × 1010 vg/b. We observed full correction of the bone phenotype at 4 × 108 and 4 × 109 in female AlplPrx1/Prx1 mice, but bones remained hypomineralized with the 4 × 106 and 4 × 107 (vg/b) doses after 70 d of treatment. We observed skeletal improvements using the 4 × 109 (vg/b) dose, but the phenotype was not fully corrected in male AlplPrx1/Prx1. Immunohistochemistry using anti-TNAP and anti-D10 antibodies showed high immunolocalization in the femurs of female AlplPrx1/Prx1 mice, while D10 immunolocalization was high in the liver of male AlplPrx1/Prx1 mice at a dose of 4 × 109 (vg/b). This sex-dependent difference was not seen in the infantile HPP model. A serum proteome analysis showed enhanced inflammatory pathways in treated AlplPrx1/Prx1 males compared to treated female mice. We also found a few areas of ectopic calcification in soft organs at the highest tested dose of 4 × 1010 (vg/b) in Alpl-/- or 4 × 109 (vg/b) in the AlplPrx1/Prx1 model. This pre-clinical study will inform the design of clinical trials to develop gene therapy in early-onset and late-onset HPP patients.


  • Open Access

    Cytotoxicity of >i/i< Mart. leaf extract (Vochysiaceae) on pre-osteoblast culture. Evaluation of cell viability and expression/activity of MMPs

    by Cintia Kazuko Tokuhara

    The use of medicinal plants with the purpose of treatment of many diseases is common. However, a scientific study to ensure the doses considered safe for consumption is required. Qualea grandiflora has...

  • Open Access

    Effects of Qualea grandiflora Extract on the Expression of MMP-14 and HIF-1α in Cultured Fibroblasts and Preosteoblasts

    by Gabriela Silva Neubern de Oliveira, Cintia Kazuko Tokuhara, Flávia Amadeu de Oliveira, Márcia Sirlene Zardin Graeff, Zohaib Nisar Khan, Luiz Leonardo Saldanha, Anne Lígia Dokkedal, Rodrigo Cardoso de Oliveira

  • In vitroandin vivoassessment of CaP materials for bone regenerative therapy. The role of multinucleated giant cells/osteoclasts in bone regeneration

    by Ana Carolina Cestari Bighetti, Tania Mary Cestari, Paula Sanches Santos, Ricardo Vinicius Nunes Arantes, Suelen Paini, Gerson Francisco Assis, Bruna Carolina Costa, Flávia Amadeu de Oliveira, Cintia Kazuko Tokuhara, Rodrigo Cardoso de Oliveira, et al.

    In this work, bone formation/remodeling/maturation was correlated with the presence of multinucleated giant cells (MGCs)/osteoclasts (tartrate‐resistant acid phosphatase [TRAP]‐positive cells) on the surface of beta‐tricalcium phosphate (β‐TCP), sintered deproteinized bovine bone (sDBB), and carbonated deproteinized bovine bone (cDBB) using a maxillary sinus augmentation (MSA) in aNew Zealandrabbit model. Microtomographic, histomorphometric, and immunolabeling for TRAP‐cells analyses were made at 15, 30, and 60 days after surgery. In all treatments, a faster bone formation/remodeling/maturation and TRAP‐positive cells activity occurred in the osteotomy region of the MSA than in the middle and submucosa regions. In the β‐TCP, the granules were rapidly reabsorbed by TRAP‐positive cells and replaced by bone tissue. β‐TCP enabled quick bone regeneration/remodeling and full bone and marrow restoration until 60 days, but with a significant reduction in MSA volume. In cDBB and sDBB, the quantity of TRAP‐positive cells was smaller than in β‐TCP, and these cells were associated with granule surface preparation for osteoblast‐mediated bone formation. After 30 days, more than 80% of granule surfaces were surrounded and integrated by bone tissue without signs of degradation, preserving the MSA volume. Overall, the materials tested in a standardized preclinical model led to different bone formation/remodeling/maturation within the same repair process influenced by different microenvironments and MGCs/osteoclasts. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 108B:282–297, 2020.


  • Top Cited Papers

    Vanadium ionic species from degradation of Ti-6Al-4V metallic implants: In vitro cytotoxicity and speciation evaluation

    by Bruna C. Costa, Cíntia K. Tokuhara, Luís A. Rocha, Rodrigo C. Oliveira, Paulo N. Lisboa-Filho, João Costa Pessoa


  • Open Access

    Updating the role of matrix metalloproteinases in mineralized tissue and related diseases

    by Cintia Kazuko Tokuhara, Mariana Rodrigues Santesso, Gabriela Silva Neubern de Oliveira, Talita Mendes da Silva Ventura, Julio Toshimi Doyama, Willian Fernando Zambuzzi, Rodrigo Cardoso de Oliveira

    Bone development and healing processes involve a complex cascade of biological events requiring well-orchestrated synergism with bone cells, growth factors, and other trophic signaling molecules and cellular structures. Beyond health processes, MMPs play several key roles in the installation of heart and blood vessel related diseases and cancer, ranging from accelerating metastatic cells to ectopic vascular mineralization by smooth muscle cells in complementary manner. The tissue inhibitors of MMPs (TIMPs) have an important role in controlling proteolysis. Paired with the post-transcriptional efficiency of specific miRNAs, they modulate MMP performance. If druggable, these molecules are suggested to be a platform for development of “smart” medications and further clinical trials. Thus, considering the pleiotropic effect of MMPs on mammals, the purpose of this review is to update the role of those multifaceted proteases in mineralized tissues in health, such as bone, and pathophysiological disorders, such as ectopic vascular calcification and cancer.


  • ZnO Nanoparticles with Different Sizes and Morphologies for Medical Implant Coatings: Synthesis and Cytotoxicity

    by B. C. Costa, E. A. Rodrigues, C. K. Tokuhara, R. C. Oliveira, P. N. Lisboa-Filho, L. A. Rocha